Medical News / From AHA 2023: Sotagliflozin (INPEFA®) is Associated with Improving Heart Failure, Atherosclerotic Events

On November 12, 2023, Lexicon Pharmaceuticals, Inc. announced a post hoc analysis of clinical data from the SCORED trial, which showcased the clinical benefit from sotagliflozin (INPEFA®) to treat heart failure and major adverse cardiovascular events as early as about 3 months. “We are pleased to support research in areas important to heart failure clinicians and payors, and we are confident that the early clinical benefit of INPEFA observed in the SCORED post hoc analysis will play a role in care decisions made by these stakeholders,” said Craig Granowitz, MD, PhD, Lexicon’s senior vice president and chief medical officer, in a press release. “Avoiding a stroke or myocardial infarction can have great benefit to both patients and the healthcare system, and we believe that the observed reductions in [major adverse cardiovascular events] as early as approximately three months are additional points of differentiation for INPEFA.” Source: MDMag. To view the third ...

read more

New research into the speed of diagnosis of hypertrophic cardiomyopathy in the United States is providing ... read more
In a recent study, a smartphone app using artificial intelligence (AI) predicted heart failure 3 weeks ... read more
Reducing sodium in diet to 4,000 mg/day significantly lowers blood pressure after 1 week, a new ... read more
New data from a trial presented at the American Heart Association Scientific Sessions 2023 suggest use ... read more